Natera Lifts 2026 Outlook As Test Volumes Climb And Japan Entry Nears
Natera (NasdaqGS:NTRA) raised its full-year 2026 revenue and gross margin guidance after reporting record test volumes.
The company cited accelerating growth in both women's health and oncology segments as key drivers.
Natera also outlined plans to commercially launch its Signatera MRD test in Japan, aiming to extend its international reach.
Natera enters this update with its stock at $219.82 and a 1 year return of 35.2%, and a 3 year return that is a very large multiple of its earlier...
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
